Company Profile
Shaperon develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials.
Its portfolio also includes NuDifin that calms wound inflammation and accelerates the regeneration of tissue, NuRalin indicated for atopic dermatitis, and NuAreatin for the treatment of alopecia areata NuCerin, a pill designed to reduce neuroinflammation. Its portfolio also includes NuSepin, which alleviates excessive systemic inflammation, and NuPulin for the treatment of inflammation-driven pulmonary fibrosis.
Additionally, it offers Papiliximab, a NanoMab-based bispecific antibody that blocks PD-L1 and CD47 for leukemia treatment. Its portfolio also includes Ovizumab, a tumor-specific immunotherapy, Regtizumab, an anti-tumor immunity, and Rbody, a NanoMabs' small size which enables the creation of LNP-mRNA therapeutics
RumiLua, a cosmeceutical ingredient to help prevent excessive skin responses while supporting the skin's natural balance and overall condition. Founded in 2008, the company is headquartered in Seoul, South Korea.